apceth™-201 are genetically engineered MSC which express the protease inhibitor Alpha-1 Antitrypsin (AAT-1) and have potent immunomodulatory and anti-inflammatory properties.

apceth™-201 therapy:

  • inhibits secretion of proinflammatory cytokines,
  • suppresses T-cell proliferation,
  • reduces NK cell-mediated cell killing,
  • shows positive impact on long-term immunoregulation by targeting both the adaptive and innate arm of the immune system.

This therapy targets diseases with pathology based on chronic inflammation and/or autoimmune process, such as Graft-vs-Host Disease (GvHD), inflammatory bowel disease (IBD), diabetes type I, vasculitis or chronic lung disease (COPD).

apceth™-201 will soon enter clinical development for GvHD, a frequent, severe and very often fatal complication of allogeneic hematopoietic stem cell transplantation (HSCT).

Click to enlarge